CD20 (188-196)

CD20 (188-196) is a short part of a membrane phosphoprotein, CD20, which is expressed on the surface of B cells. CD20 receptor is an important target for immunotherapy against B cell lymphoma. CD20 epitopes are used in antibodies CD20 production, such as the production of the first Monoclonal to be approved for the treatment of lymphoma. Applications of CD20 (188-196): CD20 (188-196) is involved in research to generate cytotoxic T lymphocytes and stimulate CTL responses against B cell diseases. The production of specific T cells and IFN-γ are quantified by ELISPOT. CD20 (188-196) has been identified as a highly immunogenic HLA-A2 restricted peptide. Results suggest that CD20 (188-196) may serve in immunotherapeutic strategies especially for vaccine development against certain type of blood cancer. CD20 (188-196) is also used in research on cell therapy as target for T cell receptor. In fact, T cells are modified in vivo to express specific T cell receptor and then inject modified cells in B cells cancer patient in order to recognized malignant B cells and treat them.